DAPT Duration Post-PCI: No Cardiovascular Benefit, Increased Bleeding in CKD Patients
No significant differences in cardiovascular events were found across DAPT duration groups in ACS patients, but prolonged DAPT (≥7 months) increased major bleeding risk in CKD patients.
Phase III
chronic kidney disease patients
Status
Positive
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The study indicates that prolonged dual antiplatelet therapy (DAPT) does not confer cardiovascular benefits and increases bleeding risks in chronic kidney disease (CKD) patients. This could lead to changes in treatment guidelines, necessitating a reevaluation of current pharmaceutical strategies for antiplatelet therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor updates on clinical guidelines regarding DAPT duration and any new studies focusing on CKD patients in the context of ACS.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.